UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K		
	Current Report	
	Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 193	
Date of Report (I	Date of earliest event reported): C	October 20, 2020
В	IOCEPT, INC	, J.
	me of registrant as specified in its	
Delaware (State or other jurisdiction of incorporation)	001-36284 (Commission File Number)	80-0943522 (I.R.S. Employer Identification No.)
5810 Nancy Ridge Drive, San Diego, CA (Address of principal executive offices)		92121 (Zip Code)
Registrant's telepl	hone number, including area code	e: (858) 320-8200
Check the appropriate box below if the Form 8-K filing is intollowing provisions:	ended to simultaneously satisfy the	filing obligation of the registrant under any of the
Written communications pursuant to Rule 425 under th	ne Securities Act (17 CFR 230.425)	
Soliciting material pursuant to Rule 14a-12 under the E	Exchange Act (17 CFR 240.14a-12)	
Pre-commencement communications pursuant to Rule	14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule	13e-4(c) under the Exchange Act (2	17 CFR 240.13e-4(c))
ecurities registered pursuant to Section 12(b) of the Securiti	es Act:	
Title of each class Common Stock, par value \$0.0001 per share	Trading Symbol(s) BIOC	Name of each exchange on which registered The Nasdaq Stock Market LLC
ndicate by check mark whether the registrant is an emerging chapter) or Rule 12b-2 of the Securities Exchange Act of 193		e 405 of the Securities Act of 1933 (§230.405 of this
Emerging growth company \Box		

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new

or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

On October 20, 2020, Bruce A. Huebner notified Biocept, Inc. (the "Company") that he will retire from the Company's Board of Directors (the "Board"), effective November 30, 2020.

(d

On October 20, 2020, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Samuel D. Riccitelli as a Class I director of the Company, effective immediately, with a term of office expiring at the 2023 annual meeting of stockholders.

Concurrently with his appointment to the Board, Mr. Riccitelli was appointed to the Audit Committee of the Board and the Science and Technology Committee of the Board.

Pursuant to the Company's non-employee director compensation policy (the "Compensation Policy"), Mr. Riccitelli (i) will receive an annual cash retainer of \$30,000 for service on the Board, an annual cash retainer of \$5,000 for service on the Science and Technology Committee of the Board, and (ii) was granted on the date of his appointment an option to purchase 10,000 shares of the Company's common stock, which vests annually over a three year period. The Compensation Policy also provides for further automatic annual option grants to purchase 10,000 shares of the Company's common stock on the date of each annual meeting of stockholders, which vest in full on the one year anniversary of the date of grant. Each of the option grants described above will vest in full in the event of a change in control (as defined in the Company's equity incentive plan). Mr. Riccitelli has also entered into the Company's standard form of Indemnification Agreement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Biocept, Inc.

Date: October 21, 2020 By: /s/ Michael W. Nall

Michael W. Nall Chief Executive Officer